Reunion Neuroscience, Inc., today announced that it will share the full results of the RECONNECT, a Phase 2 trial evaluating luvesilocin in adult female patients with moderate-to-severe postpartum depression (PPD), in an oral presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting 2026 – Psychiatry and AI: Promises,...
Reunion Neuroscience, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to luvesilocin (formerly RE104) for the treatment of postpartum depression (PPD)....
Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced its participation in the following upcoming conferences:...
Reunion Neuroscience, Inc., today announced the full results of RECONNECT, a Phase 2 clinical trial evaluating RE104 in adult female patients with moderate-to-severe PPD. The data were presented at the American College of Neuropsychopharmacology (ACNP) Annual Meeting and the poster presentation is now available on the Reunion website...
Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced program updates and anticipated 2026 milestones. ...
Reunion Neuroscience Inc. today announced the closing of its Series A financing. Under the amended terms of the Series A financing, because certain efficacy parameters were met including achieving a statistically significant and clinically meaningful outcome for the RECONNECT study, the final tranche of the financing increased from $21 to...
Reunion Neuroscience Inc. today announced the closing of its Series A financing. Under the amended terms of the Series A financing, because certain efficacy parameters were met including achieving a statistically significant and clinically meaningful outcome for the RECONNECT study, the final tranche of the financing increased from $21 to...
Reunion Neuroscience Inc. today announced positive topline results from its RECONNECT Phase 2 clinical trial evaluating RE104 in adult female patients with moderate-to-severe postpartum depression (PPD). ...
Reunion Neuroscience Inc. today announced the publication of a manuscript entitled “Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study,” describing the results of a Phase 1 study of RE104 in the peer-reviewed Journal of Clinical Psychopharmacology....
Reunion Neuroscience, Inc. today announced the completion of patient enrollment and the last patient dosed in RECONNECT, a Phase 2 clinical trial evaluating RE104 in adult female patients with moderate-to-severe postpartum depression (PPD). ...